정규장
Log in Sign up
RDHL
RDHL
Redhill Biopharma Ltd ADR
7월 28일 1:02 PM ET (한국 7/29 02:02)
$0.70
+0.07 ▲ +10.53%

레드힐바이오팜즈(RDHL) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$4M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +11% · 고점 -75%
애널리스트
-
F
Fundamental health
vs. 미분류 초소형주· based on 2 axes
수익성
데이터 부족
성장
Top 50%
밸류에이션
데이터 부족
재무 안정
Top 100%
Index -P/E -EPS (ttm) -Insider Own 11.09%Shs Outstand 6.1MPerf Week -
Market Cap 0.00BForward P/E -EPS next Y -Insider Trans -97.79%Shs Float 5.4MPerf Month -18.61%
Enterprise Value 0.00BPEG -EPS next Q -Inst Own 2.76%Short Float 0.37%Perf Quarter -31.71%
Income -P/S -EPS this Y -Inst Trans 1.36%Short Ratio 0.09Perf Half Y -48.53%
Sales -P/B -EPS next 5Y -ROA -Short Interest 0.02MPerf YTD -32.04%
Book/sh -1.93P/C 1.4EPS past 3/5Y 95.56% 86.32%ROE -52W High -74.91% ($2.79)Perf Year -59.06%
Cash/sh 0.5P/FCF -Sales past 3/5Y -83.27% -66.14%ROIC -52W Low 11.11% ($0.63)Perf 3Y -97.7%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 94.66%Gross Margin -Volatility(W/M) 7.32% 8.62%Perf 5Y -99.99%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.07Perf 10Y -99.99%
Dividend Ex-Date -Quick Ratio 0.42EPS Q/Q 102.33%Profit Margin -RSI (14) 41.43Recom -
Dividend Gr. 3/5Y -Current Ratio 0.56Sales Q/Q -90.21%SMA20 -4.55% ($0.73)Beta 4.99Target Price $7.75
Payout -Debt/Eq -Earnings 2026/4/27SMA50 -17.72% ($0.85)Rel Volume 0.12Prev Close $0.63
Employees 13LT Debt/Eq -EPS/Sales Surpr. -SMA200 -33.33% ($1.05)Avg Volume(3M) 0.22MPrice $0.7
IPO 2013/1/7Option/Short No/YesTrades 112Volume 25,340Change 10.53%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Redhill Biopharma Ltd ADR (RDHL) Investment Analysis

What kind of company is Redhill Biopharma Ltd ADR?

레드힐바이오팜즈(RDHL)
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility

💊 RedHill Biopharma () is a specialty pharmaceutical company headquartered in Israel that focuses on gastrointestinal, infectious disease, and oncology therapeutics. Its core revenue driver is Talicia, a treatment for Helicobacter pylori, and the company is working to reduce losses and improve its fundamentals through a co-promotion agreement with Cumberland () in 2025 and progress in its late-stage clinical pipeline.

Learn more about Redhill Biopharma Ltd ADR →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5706
Employees13people
IPO2013/01/07
Current Price$0.70 ≈ 959원
NASD · Israel

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 4월 27일 (월) · 장 시작 전

Is it profitable?

Financial health caution
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.56
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.42
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$7.75
현재가 대비 +1007.1%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+95.6%
우수
My positionTop 5%
Low range Average High range
미분류 초소형주 Median 25.4% · Top tier
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+86.3%
우수
My positionTop 5%
Low range Average High range
미분류 초소형주 Median 14.6% · Top tier
Past 5-Year Revenue
How much revenue grew over the past 5 years
-66.1%
매우 부진
My positionBottom 5%
Low range Average High range
미분류 초소형주 Median 2.8% · Bottom tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-90.2%
매우 부진
My positionBottom 5%
Low range Average High range
미분류 초소형주 Median -2.6% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
RDHL -100.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-168.3%p
Significantly behind the market
vs Health Care (XLV)
-124.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-75.1%p
Significantly behind the market
vs Health Care (XLV)
-78.8%p
Significantly behind the sector average
Rank among peers
5-year return Lowest among peers Based on 28 peers
1-year return Lower-Mid (lower 34%) Based on 36 peers
Current position within 52-week range
Low (-11.1%p) High (-74.9%p)
Current price is 11.1% above the 52-week low and 74.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-42.2%
Annualized volatility
74.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $0.70 below the midline ($0.73). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

Current diagnosis · 2026-07-27
Golden cross — bullish reversal signal

MACD(-0.051) crossed above Signal(-0.052). Trend reversal possible; read as a buy entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 41.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 43.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Valuation data is insufficient

Key metrics such as PER and PBR are unavailable, so valuation is omitted.

Who owns it?

Ownership flow is positive
Insider net selling -97.8% · Institutional net buying +1.4% · Short interest light 0.4%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-97.8%
Insiders large net selling
🏦 Institutions (funds & investors)
+1.4%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 2.8%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 11.1%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 86.2%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
0.4%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 89 days Little change
Short interest days to cover
0.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 6.1M주
Float (tradable shares) 5.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
RDHL RDHL This Stock
$4.3M- - - - +10.5%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 레드힐바이오팜즈(RDHL)?

레드힐바이오팜즈(RDHL) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of RDHL?

The market cap of RDHL is approximately $4M, ranking 5,706 within its sector.

What is the 52-week high and low for RDHL?

RDHL has recorded a 52-week high of $2.79 and a low of $0.63.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.